VivoSeq
Oncology

Metastatic Salivary Gland Carcinoma

4

Pipeline Programs↗

1

Active Trials↗

2

Companies Involved↗

Metastatic Salivary Gland Carcinoma is an early-stage landscape with 4 programs across 2 companies. The most active players are Avyxa, AstraZeneca.

Intelligence

Pipeline Metrics

Competitive Density

25/100

Pipeline Velocity

0/100

Mech. Concentration

50/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Avyxa

1 program

Phase 2AstraZeneca logo

AstraZeneca

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

4programs
Antibody–drug conjugate250%
Small molecule125%
Monoclonal antibody125%

Modality classified for 100% of 4 pipeline programs.

Analysis

Trial Status

1

clinical trials

Recruiting1 · 100%

Clinical Trials

Trial Activity

A Phase II Trial of HER2-Targeted Therapies for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
Recruiting·NRG Oncology·Phase 2·NCT05408845·146 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)